ABSTRACT
The incidence of new cases of prostate cancer in the United States is estimated at 217,730 for 2010, of which 32,050 men will succumb. Only lung cancer has a higher mortality rate among all other forms of malignancies [1]. Although 1 man in 6 will be diagnosed with prostate cancer during his lifetime, only 1 man in 34 will die of it. Often prostate cancer grows slowly, and “watchful waiting” is the chosen course of intervention [2]. However, there are aggressive forms that require early diagnosis and treatment before metastasis to the bone or other organs occurs. There is a clear need for highly specic and sensitive biomarkers for early diagnostics and treatment.
